Application of Liposomes in Pulmonary Drug Delivery and Respiratory Disease Treatment

With environmental problems becoming more and more serious, the incidence rate of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and lung infection continues to rise, posing a serious threat to human health. Traditional drugs have the limitations of poor targeting, short duration of efficacy and difficult to control drug release. However, novel nanomedicines can make up for these shortcomings, improve drug efficacy and accelerate patient recovery. This article will explore the application mechanism and clinical value of lipid carriers in the treatment of lung diseases, with a focus on analyzing the unique advantages of solid lipid nanoparticles (SLNs), liposomes, and other carriers for drug delivery. Research has shown that lipid carriers can significantly enhance the ability of drugs to penetrate the mucosal barrier by regulating particle size and surface modification, and PEG-modified nanoparticles exhibit excellent mucosal permeability and cellular uptake efficiency in asthma models. In addition, drug-loaded SLN can reduce cell infiltration in COPD model mice with bronchitis (inflammation factor levels decreased by 42%), and improve alveolar epithelial hyperplasia and excessive mucus secretion]. Finally, lipid carriers prolong drug action time through their sustained release properties, and their biocompatibility can reduce the risk of immune rejection. This study can not only provide efficient treatment plans for lung diseases but also reduce drug risks, greatly improving the efficiency of lung disease treatment.